Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Single and dual agonists The fundamental difference between these two molecules is that semaglutide is a GLP-1 agonist, i.e., it has a strong structural similarity (95%) with this hormone and specifically activates its receptor, while tirzepatide is a dual agonist, i.e., it has a hybrid structure that allows it to activate both GLP-1 and GIP receptors (Figure 2)
Both Use Gradual Dosing, But Tirzepatide Offers More Flexibility Semaglutide uses a fixed, stepup approach: Treatment begins with a low starting dose, which is gradually increased over several weeks
Common sense really isn't that common with eating anymore
The Pharmacy Compounding Advisory Committee (PCAC) may have voted to give the peptides FDA approval, but it does not greenlight pharmacy compounders to make gray market peptides that are currently labeled for research purposes only and not for human consumption (as a legal workaround for pharmaceutical compounders)
